Biolargo, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 16, 2021 at 04:26 pm EDT
Share
BioLargo, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 464,000 compared to USD 418,000 a year ago. Operating loss was USD 1.702 million compared to USD 2.005 million a year ago. Net loss was USD 1.622 million compared to USD 2.426 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. For the half year, total revenue was USD 1.035 million compared to USD 856,000 a year ago. Operating loss was USD 3.560 million compared to USD 3.706 million a year ago. Net loss was USD 3.253 million compared to USD 4.699 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.03 a year ago.
BioLargo, Inc. is a cleantech and life sciences innovator and engineering services solution provider. The Company operates through six segments: ONM Environmental, Clyra Medical Technologies (Clyra Medical), BioLargo Engineering (BLEST), BioLargo Canada, Inc. (Canada), BioLargo Energy Technologies, Inc. (BETI), and BioLargo Equipment Solutions & Technologies, Inc. (BEST). ONM Environmental segment engaged in selling odor and volatile organic control products and services. Clyra Medical segment develops and sells medical products based on its technologies. BLEST segment provides professional engineering services on a time and materials basis for outside clients and supports its internal operations as needed. Its Canada segment is the main hub of its scientists researching and developing its technologies. Its BETI segment is engaged in developing its proprietary battery technology. BEST segment manages the sales and distribution of its water treatment products and related services.